5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 5.79▼ | 5.88▼ | 5.89▼ | 5.75▲ | 5.35▲ |
MA10 | 5.85▼ | 5.88▼ | 5.86▼ | 5.48▲ | 4.94▲ |
MA20 | 5.90▼ | 5.85▼ | 5.80▼ | 5.16▲ | 5.13▲ |
MA50 | 5.90▼ | 5.74▲ | 5.53▲ | 4.78▲ | 5.67▲ |
MA100 | 5.85▼ | 5.49▲ | 5.26▲ | 5.11▲ | 6.57▼ |
MA200 | 5.76▲ | 5.23▲ | 4.95▲ | 5.45▲ | 6.23▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.023▼ | -0.018▼ | -0.009▼ | 0.085▲ | 0.152▲ |
RSI | 27.195▼ | 44.959▼ | 52.013▲ | 66.325▲ | 55.187▲ |
STOCH | 14.352▼ | 50.586 | 48.343 | 85.000▲ | 66.359 |
WILL %R | -91.667▼ | -91.667▼ | -79.012▼ | -25.000▲ | -19.486▲ |
CCI | -114.946▼ | -236.492▼ | -20.009 | 102.066▲ | 112.240▲ |
Thursday, June 12, 2025 05:00 PM
New corporate presentation and management webcast available for replay on websiteCalgary, Alberta--(Newsfile Corp. - May 7, 2025) - OBSIDIAN ENERGY LTD. (TSX: OBE) (NYSE American: OBE ...
|
Thursday, June 12, 2025 01:01 AM
LONDON - Autolus Therapeutics ’ (NASDAQ: AUTL) obecabtagene autoleucel (obe-cel) demonstrated sustained remission in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia ...
|
Wednesday, June 11, 2025 05:00 PM
“Obe-cel’s durability of response without any ... About Autolus Therapeutics plc Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 5.80 | 5.885 | 5.74 | 5.76 | 116,839 |
13/06/25 | 6.04 | 6.09 | 5.82 | 5.95 | 656,648 |
12/06/25 | 5.68 | 5.7653 | 5.61 | 5.74 | 352,173 |
11/06/25 | 5.63 | 5.87 | 5.5475 | 5.78 | 442,724 |
10/06/25 | 5.44 | 5.605 | 5.44 | 5.53 | 289,211 |
09/06/25 | 5.31 | 5.465 | 5.29 | 5.36 | 357,284 |
06/06/25 | 5.21 | 5.31 | 5.08 | 5.28 | 365,660 |
05/06/25 | 5.17 | 5.20 | 5.04 | 5.14 | 286,904 |
04/06/25 | 5.29 | 5.3608 | 5.055 | 5.11 | 298,974 |
03/06/25 | 5.01 | 5.25 | 4.98 | 5.19 | 325,938 |
|
|
||||
|
|
||||
|
|